# Secondary Modification of S100B Influences Anti Amyloid-β Aggregation Activity and Alzheimer’s Disease Pathology

**Authors:** Romina Coelho, Chiara A. De Benedictis, Ann Katrin Sauer, António J. Figueira, Hélio Faustino, Andreas M. Grabrucker, Cláudio M. Gomes

PMC · DOI: 10.3390/ijms25031787 · International Journal of Molecular Sciences · 2024-02-01

## TL;DR

Oxidized S100B protein is more effective at preventing amyloid-beta aggregation and reducing Alzheimer's disease toxicity than non-oxidized S100B.

## Contribution

This study reveals that oxidation of S100B enhances its anti-aggregation activity and alters downstream inflammatory signaling in Alzheimer's disease.

## Key findings

- Oxidized S100B prevents amyloid-beta aggregation more effectively than non-oxidized S100B.
- Oxidation of S100B rescues Aβ toxicity in a cell culture model of Alzheimer's disease.
- Oxidized S100B disrupts a feedback loop involving IL-17 and IFN-α2 expression.

## Abstract

Proteinaceous aggregates accumulate in neurodegenerative diseases such as Alzheimer’s Disease (AD), inducing cellular defense mechanisms and altering the redox status. S100 pro-inflammatory cytokines, particularly S100B, are activated during AD, but recent findings reveal an unconventional molecular chaperone role for S100B in hindering Aβ aggregation and toxicity. This suggests a potential protective role for S100B at the onset of Aβ proteotoxicity, occurring in a complex biochemical environment prone to oxidative damage. Herein, we report an investigation in which extracellular oxidative conditions are mimicked to test if the susceptibility of S100B to oxidation influences its protective activities. Resorting to mild oxidation of S100B, we observed methionine oxidation as inferred from mass spectrometry, but no cysteine-mediated crosslinking. Structural analysis showed that the folding, structure, and stability of oxidized S100B were not affected, and nor was its quaternary structure. However, studies on Aβ aggregation kinetics indicated that oxidized S100B was more effective in preventing aggregation, potentially linked to the oxidation of Met residues within the S100:Aβ binding cleft that favors interactions. Using a cell culture model to analyze the S100B functions in a highly oxidative milieu, as in AD, we observed that Aβ toxicity is rescued by the co-administration of oxidized S100B to a greater extent than by S100B. Additionally, results suggest a disrupted positive feedback loop involving S100B which is caused by its oxidation, leading to the downstream regulation of IL-17 and IFN-α2 expression as mediated by S100B.

## Linked entities

- **Proteins:** S100B (S100 calcium binding protein B), ab (abrupt), IL17A (interleukin 17A), IFNA2 (interferon alpha 2)
- **Diseases:** Alzheimer’s Disease (MONDO:0004975), Alzheimer's disease (MONDO:0004975)

## Full-text entities

- **Genes:** SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}, IFNA2 (interferon alpha 2) [NCBI Gene 3440] {aka IFN-alpha-2, IFN-alphaA, IFNA, IFNA2B, leIF A}, S100B (S100 calcium binding protein B) [NCBI Gene 6285] {aka NEF, S100, S100-B, S100beta}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}
- **Diseases:** toxicity (MESH:D064420), AD (MESH:D000544), neurodegenerative diseases (MESH:D019636)
- **Chemicals:** cysteine (MESH:D003545), methionine (MESH:D008715)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10855146/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC10855146/full.md

## References

80 references — full list in the complete paper: https://tomesphere.com/paper/PMC10855146/full.md

---
Source: https://tomesphere.com/paper/PMC10855146